skip to main content
Guest
My Research
My Account
Sign out
Sign in
This feature requires javascript
Library Search
Find Databases
Browse Search
E-Journals A-Z
E-Books A-Z
Citation Linker
Help
Language:
English
Vietnamese
This feature required javascript
This feature requires javascript
Primo Search
All Library Resources
All
Course Materials
Course Materials
Search For:
Clear Search Box
Search in:
All Library Resources
Or hit Enter to replace search target
Or select another collection:
Search in:
All Library Resources
Search in:
Print Resources
Search in:
Digital Resources
Search in:
Online E-Resources
Advanced Search
Browse Search
This feature requires javascript
Search Limited to:
Search Limited to:
Resource type
criteria input
All items
Books
Articles
Images
Audio Visual
Maps
Graduate theses
Show Results with:
criteria input
that contain my query words
with my exact phrase
starts with
Show Results with:
Search type Index
criteria input
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
Show Results with:
in the title
Show Results with:
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
This feature requires javascript
Cardiovascular risk in chronic kidney disease
Digital Resources/Online E-Resources
Citations
Cited by
View Online
Details
Recommendations
Reviews
Times Cited
External Links
This feature requires javascript
Actions
Add to My Research
Remove from My Research
E-mail
Print
Permalink
Citation
EasyBib
EndNote
RefWorks
Delicious
Export RIS
Export BibTeX
This feature requires javascript
Title:
Cardiovascular risk in chronic kidney disease
Author:
Ha, Jeffrey
Subjects:
anaemia
;
anticoagulation
;
atrial fibrillation
;
Cardiology (incl. cardiovascular diseases)
;
cardiovascular disease
;
chronic kidney disease
;
epidemiology
;
Haematology
;
heart failure
;
Nephrology and urology
Description:
Background A high burden of cardiovascular disease in chronic kidney disease (CKD) confers an increased risk of adverse cardiovascular events and mortality. However, compared with atherosclerotic cardiovascular disease, elevated risk of nonatherosclerotic cardiovascular events such as atrial fibrillation (AF) and heart failure is underappreciated and understudied in CKD. Optimal strategies for recognising and mitigating these risks in CKD are limited. This requires systematic evaluation of risk profiles and therapeutic interventions to manage cardiovascular risk across the spectrum of CKD. Aims The overarching aim of this thesis is to generate high-quality evidence to guide risk stratification and management of cardiovascular disease in CKD by: 1. improved delineation of markers for CKD (albuminuria and estimated glomerular filtration rate [eGFR]) as independent risk factors for incident AF and heart failure; and, 2. systematic evaluation of the cardiovascular risk-benefit profiles of newer therapeutic interventions across the range of kidney function, including kidney failure requiring dialysis. Methods The research program was divided into two themes: 1. Cardiovascular risk evaluation through: i. a systematic review to investigate the association of eGFR and urine albumin-to-creatinine ratio (UACR) with risk of incident AF (38 studies, 28,470,249 participants with 530,041 incident AF cases); and, ii. an observational study to analyse the independent association and interaction of albuminuria and kidney function with risk of hospitalisation for heart failure (HHF) or cardiovascular death, in a post hoc analysis of participant-level data pooled from randomised controlled trials (RCTs) involving 14,434 participants with type 2 diabetes (T2D) 2. Evaluation of treatments through: i. a systematic review and meta-analysis of RCTs assessing the benefits and risks of oral anticoagulants in CKD, including dialysis-dependent kidney failure (45 trials, 34,082 participants); and, ii. a binational population-based study assessing safety (risk of bleeding) and effectiveness (risk of all-cause death or stroke) of rivaroxaban versus warfarin across a broad range of kidney function in 55,568 adults with AF; and, iii. a systematic review and meta-analysis of RCTs assessing cardiovascular safety of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) compared with ESA (erythropoiesis stimulating agent) or placebo in patients with dialysis-dependent and non-dialysis CKD (25 trials, 26,478 participants). Results This thesis has demonstrated an exposure-dependent association between the markers of CKD and increased risk of incident AF, and in T2D, increased risk of HHF or cardiovascular death. It has systematically defined the progressive increase in risk of incident AF with lower eGFR and higher albuminuria, independent of established cardiovascular risk factors. Patients with a combination of both lower eGFR and higher albuminuria were also at a multi-fold greater risk of HHF or cardiovascular death. Direct oral anticoagulants (DOACs) demonstrated a benefit–risk profile superior to vitamin K antagonists (VKAs) in early-stage CKD. For advanced CKD or end-stage kidney disease (ESKD), there was limited trial evidence to establish benefits or harms of either VKAs or DOACs. Instead, observational data showed that the safety and effectiveness of the DOAC rivaroxaban compared with warfarin was consistent across a broad range of kidney function in adults with AF. Long-term cardiovascular safety of HIF-PHIs and ESAs was comparable in adults with dialysis-dependent and non-dialysis CKD. Effective strategies to reduce cardiovascular risk in advanced CKD and ESKD are limited, identifying a critical evidence gap that should be the focus of further research. Conclusions Our findings support the utility of markers for CKD to identify individuals at high risk of incident AF, and in patients with T2D, increased risk of HHF or cardiovascular death. This research shows that eGFR and UACR should be routinely included in cardiovascular risk assessment. Certainty of evidence for interventions to manage cardiovascular risk varies according to CKD severity. Our findings suggest that DOACs should be the treatment of choice for patients with AF and non-dialysis CKD, with low-certainty evidence that DOACs may have an acceptable risk-benefit profile in patients with dialysis-dependent ESKD. HIF-PHIs are an acceptable alternative to ESAs in patients with dialysis-dependent ESKD for the treatment of anaemia, and in non-dialysis CKD they are also a reasonable treatment option. Thus, this thesis has generated high-quality evidence to guide cardiovascular risk management in CKD and support future trials. Source: TROVE
Creation Date:
2024
Language:
English
Source:
Trove Australian Thesis (Full Text Open Access)
This feature requires javascript
This feature requires javascript
Back to results list
This feature requires javascript
This feature requires javascript
Searching Remote Databases, Please Wait
Searching for
in
scope:(TDTS),scope:(SFX),scope:(TDT),scope:(SEN),primo_central_multiple_fe
Show me what you have so far
This feature requires javascript
This feature requires javascript